Immune recall enhances cross-reactive antibody longevity after a large wave of SARS-CoV-2 breakthrough infection  

作　　者：Dan Li Qingfei Chu Kang Li Lanjuan Li Yiming Shao 

机构地区：[1]State Key Laboratory for Diagnosis and Treatment of Infectious Diseases,National Clinical Research Center for Infectious Diseases,National Medical Center for Infectious Diseases,Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases,The First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310003,China [2]National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases,National Center for AIDS/STD Control and Prevention,Chinese Center for Disease Control and Prevention,Beijing 102206,China

出　　处：《Signal Transduction and Targeted Therapy》2024年第9期3563-3565,共3页信号转导与靶向治疗（英文）

基　　金：supported by grants from the National Natural Science Foundation of China(U20A20362);The First Affiliated Hospital,Zhejiang University School of Medicine,State Key Laboratory of Infectious Disease Prevention and Control Grant(no.2021SKLID304 and no.2020SKLID102);Chinese Preventive Medicine Association Vaccine and Immunization Youth Talent Promotion Project(CPMAQT_YM0301).

摘　　要：Dear Editor,Although coronavirus disease 2019(COVID-19)is no longer deemed a“Public Health Emergency of International Concern”,the global transmission dynamics of SARS-CoV-2 have shifted due to vaccination,emergency of virus variants,and pre-existing coronavirus immunity.1–3 It remains unclear how cross-reactive and pre-existing humoral immunity might impact the effectiveness of vaccines and antibodies against new viral mutations.4,5 This study seeks to elucidate the cross-reactivity of coronavirus antibodies induced by previously unencountered Omicron BA.5/BF.7 variants in the breakthrough infection(BTI)population.

关 键 词：immunity INFECTION BREAKTHROUGH 

分 类 号：R563.1[医药卫生—呼吸系统]